Previous Close | 2.9900 |
Open | 2.9900 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 1200 |
Day's Range | 2.9714 - 3.0500 |
52 Week Range | 1.1800 - 4.6200 |
Volume | |
Avg. Volume | 180,047 |
Market Cap | 109.099M |
Beta (5Y Monthly) | 1.53 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.3350 |
Earnings Date | Mar 15, 2023 - Mar 20, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for BDTX
A look at the shareholders of Black Diamond Therapeutics, Inc. ( NASDAQ:BDTX ) can tell us which group is most...
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the 41st
CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman of the Board of Directors, Robert (Bob) A. Ingram, has stepped down due to personal reasons. Existing Board member, Mark Velleca, M.D., Ph.D., has been appointed to succeed Mr. Ingram as the next Chairman. “Bob’s counsel, expertise and partnership have